Skip to content
MARKETS / BALCAO / CHUC
BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Charlie's Holdings, Inc. CHUC

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$20.9M
▲ 169.4% YoY
$4.5M
$-5.8M
In brief

What this company does

In December, the Company signed a definitive licensing agreement with IKE Tech LLC (“IKE”) to commercialize the first-ever AI-powered blockchain-based age-gating system for vapor products in the United States. Metatine is the proprietary ingredient in the Company’s SBX Disposable device (“SBX”) product line. We had 35 full-time employees as of March 31, 2026. We are a Nevada corporation originally incorporated in 2001. Our principal executive offices are located at 1007 Brioso Drive, Costa Mesa, CA 92627 and our phone number is (949) 531-6855.

Written from the business description in Charlie's Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 1 April 2026. Every sentence was checked against that document before publication.

Growth
USD 20.9M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 20.9 · Net income 4.5
10M20M-5M-10M201020122014201620182020202220242025
Compound annual growth
−7.5%
+4.6%
+13.1%
+15.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +4.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
22 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -10.4% · Net 21.5%
-100%-200%-300%201020122014201620182020202220242025
ROE
FY2025 · ROE 547.7%
200%400%600%-500%-1000%-1500%201020122014201620182020202220242025

Each USD of equity produced 548 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -5.8
4M-4M-8M201020122014201620182020202220242025
Net buybacks $M Dividends $M
FY2022 · Dividends 0.0 · Net buybacks —
8M16M20182019202020212022

Total assetsUSD 11.6M
EquityUSD 3.4M
Current ratio1.41×

Equity funds 30% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.00.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0·····0.0−0.0−0.0−0.0−0.0−0.0−0.0··
Income tax $B0.00.00.0−0.00.00.00.00.00.00.0······
Net income $B0.0−0.0−0.0−0.00.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0··
EPS, diluted $0.02−0.02−0.01−0.010.01−0.040.000.00−0.07−0.05−0.16−0.23−0.26·−0.09−0.20
Dividend / sh $················
Payout %···−018−0−858110········
ROE %547.7·−262.8−65.9··−1759.0617.0···−351.4−160.2−235.8··
Shares out B0.270.260.230.220.210.1918.970.140.220.120.110.050.03·0.050.02

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 71 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 22 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image